Modality
ERT
MOA
IL-23i
Target
IL-23
Pathway
Innate Imm
PompeAsthmaPSP
Development Pipeline
Preclinical
Jul 2017
→ Feb 2027
PreclinicalCurrent
NCT03346847
2,698 pts·Asthma
2017-07→2027-02·Terminated
NCT05007528
1,002 pts·Asthma
2022-11→2025-09·Not yet recruiting
3,700 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-09-107mo agoInterim· Asthma
2026-03-192w agoPDUFA· Asthma
2027-02-2011mo awayInterim· Asthma
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Preclinical
Termina…
Preclinical
Not yet…
Catalysts
Interim
2025-09-10 · 7mo ago
Asthma
PDUFA
2026-03-19 · 2w ago
Asthma
Interim
2027-02-20 · 11mo away
Asthma
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03346847 | Preclinical | Asthma | Terminated | 2698 | LiverFat |
| NCT05007528 | Preclinical | Asthma | Not yet recr... | 1002 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 | |
| Gelisertib | Samsung Biologics | Approved | IL-23 |